Q1 2018 Sentiment Xencor Inc (NASDAQ:XNCR)

June 17, 2018 - By Linda Rogers

Sentiment for Xencor Inc (NASDAQ:XNCR)

Xencor Inc (NASDAQ:XNCR) institutional sentiment increased to 1.7 in Q1 2018. Its up 0.49, from 1.21 in 2017Q4. The ratio improved, as 63 investment professionals opened new and increased stock positions, while 37 decreased and sold their stakes in Xencor Inc. The investment professionals in our partner’s database now hold: 43.81 million shares, up from 36.52 million shares in 2017Q4. Also, the number of investment professionals holding Xencor Inc in their top 10 stock positions increased from 0 to 2 for an increase of 2. Sold All: 7 Reduced: 30 Increased: 35 New Position: 28.

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on discovery and development of engineered monoclonal antibodies to treat severe and life-threatening diseases with unmet medical needs. The company has market cap of $2.24 billion. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. It currently has negative earnings. The companyÂ’s product candidates include XmAb5871, an immune inhibitor, which is in Phase II clinical trials for the treatment of autoimmune diseases; XmAb7195, an immune inhibitor that is in Phase I clinical for use in treating asthma and allergic diseases; XmAb14045, a bispecific oncology candidate, which is in phase I clinical trials for the treatment of acute myeloid leukemia; and XmAb13676 that is in phase I clinical trials for the treatment of B-cell malignancies.

The stock decreased 1.83% or $0.75 during the last trading session, reaching $40.18. About 512,844 shares traded or 37.74% up from the average. Xencor, Inc. (NASDAQ:XNCR) has risen 82.34% since June 17, 2017 and is uptrending. It has outperformed by 69.77% the S&P500.

Analysts await Xencor, Inc. (NASDAQ:XNCR) to report earnings on August, 6. They expect $-0.55 earnings per share, down 266.67 % or $0.40 from last year’s $-0.15 per share. After $-0.62 actual earnings per share reported by Xencor, Inc. for the previous quarter, Wall Street now forecasts -11.29 % EPS growth.

First Light Asset Management Llc holds 4.59% of its portfolio in Xencor, Inc. for 697,756 shares. Redmile Group Llc owns 3.20 million shares or 3.71% of their US portfolio. Moreover, Bvf Inc Il has 2.74% invested in the company for 902,000 shares. The New York-based Perceptive Advisors Llc has invested 1.11% in the stock. Rhenman & Partners Asset Management Ab, a Sweden-based fund reported 300,000 shares.

Since January 1, 0001, it had 0 insider buys, and 6 insider sales for $3.02 million activity.

Xencor, Inc. (NASDAQ:XNCR) Ratings Coverage

Ratings analysis reveals 86% of Xencor Inc’s analysts are positive. Out of 7 Wall Street analysts rating Xencor Inc, 6 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $2800 while the high is $56. The stock’s average target of $40 is -0.45% below today’s ($40.18) share price. XNCR was included in 13 notes of analysts from February 22, 2018. The firm has “Buy” rating by Cantor Fitzgerald given on Tuesday, May 8. Wedbush maintained Xencor, Inc. (NASDAQ:XNCR) rating on Monday, March 19. Wedbush has “Outperform” rating and $39 target. Piper Jaffray maintained the shares of XNCR in report on Wednesday, February 28 with “Buy” rating. On Thursday, March 29 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm has “Buy” rating by Piper Jaffray given on Thursday, March 15. The rating was maintained by Cantor Fitzgerald with “Buy” on Wednesday, February 28. The firm has “Buy” rating by Piper Jaffray given on Thursday, April 26. Cantor Fitzgerald initiated the stock with “Buy” rating in Thursday, February 22 report. As per Wednesday, May 9, the company rating was maintained by Canaccord Genuity. On Monday, March 26 the stock rating was maintained by Piper Jaffray with “Buy”.

More recent Xencor, Inc. (NASDAQ:XNCR) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Biomarin Gets FDA Nod, Amarin Settles with Teva, Merck’s Cancer Drug Review …” on May 25, 2018. Also Streetinsider.com published the news titled: “BTIG Starts Xencor, Inc. (XNCR) at Buy” on June 06, 2018. Seekingalpha.com‘s news article titled: “Premarket analyst action – healthcare” with publication date: June 07, 2018 was also an interesting one.

Xencor, Inc. (NASDAQ:XNCR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.